image

Key updates

What's new on Wikilite
Section Contents
  • What's new on Wikilite
    • Key updates


Date Publication Update
25/01/2018
Kyle 2018 [1016]Section 13.3. MGUS as the precursor condition for MM and related disorders
25/01/2018
Kristinsson 2009 [1017]Section 13.3. MGUS as the precursor condition for MM and related disorders
24/01/2018
Palumbo 2015 [1012]
Section 20.1. Multiple Myeloma Prognosis: Introduction
16/01/2018
Thompson 2017 [1011]
Section 3.6.1. Cerebrospinal fluid and free light chains: Introduction
12/01/2018
ASH Abstracts [1010]Section 28.7. Prognostic value of sFLC response
22/12/2017
Valencia-Vera 2017 [999]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
21/12/2017
Yagci 2015 [1007]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Tacchetti 2016 [1006]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Pratt 2015 [1005]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Gentili 2015 [1004]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Martinez-Lopez 2015 [1003]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Garcia 2016 [1002]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Fraser 2017 [1008]Section 35.2. Chronic Kidney Disease
Tandon 2017 [1000]Section 28.7. Prognostic value of sFLC response
Bossuyt 2017 [1001]Section 8.6.1. Comparison of absolute values
Section 8.7. Compliance with guidelines
17/11/2017
ASH abstracts Section 14.1. Introduction
Section 14.2. Monoclonal sFLCs and SMM progression
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.3.2. Early sFLC response predicts outcome
Section 20.5. HLC analysis during response assessment
Section 23.6. Organisational and cost implications of screening algorithms
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.5. Monitoring patients with AL amyloidosis
Section 32.1. Waldenström's macroglobulinaemia Introduction
Section 32.5. Use of sFLC and HLC analysis in IgM MGUS and asymptomatic WM
16/11/2017
Campbell 2017 [920]Section 8.2. Overview of commercial FLC assays
Section 8.4. Analytical performance of monoclonal and polyclonal antibody-based FLC assays
Section 8.4.1. Calibration
Section 8.5.1. Normal reference intervals
*NEW* Section 8.6.1. Comparison of absolute values
13/11/2017
Heaney 2017 [980]*NEW* Section 8.6.1. Comparison of absolute values
*NEW* Section 8.6.2. Diagnostic performance in MM
*NEW* Section 8.6.4. Monitoring MM
26/09/2017
Heaney 2017 [979]Section 8.5.2. Renal reference interval
16/11/2017
Kubicki 2017 [985]*NEW* Section 8.6.4. Monitoring MM
Lutteri 2015 [982]*NEW* Section 8.6.4. Monitoring MM
*NEW* Figure 8.11. Freelite indicates LCMM progressive disease before N Latex FLC.
Popat 2015 [984]*NEW* Section 8.6.4. Monitoring MM
Butticaz 2015 [983]*NEW* Section 8.6.4. Monitoring MM
Deutscher-Chertow 2014 [981]*NEW* Section 8.6.4. Monitoring MM
13/11/2017
Michallet 2017 [978]Section 18.4.1. HLC assays are quantitative and non-subjective
Section 18.4.5. Discrepancies between HLC and IFE during follow-up
Section 20.5. HLC analysis during response assessment
Section 20.6. Prognostic value of combining sFLC and HLC measurements
26/09/2017
Rezk 2017 [976]Section 28.7.2. sFLC response and renal outcome
26/09/2017
Dittrich 2017 [973]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
26/09/2017
Milani 2017 [974]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
26/09/2017
Sidana 2017 [975]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
11/09/2017
AACC 2017 abstracts Section 11.4. Antigen excess
Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 13.1. MGUS definition and frequency
Section 16.3. Monitoring nonsecretory multiple myeloma
Section 23.1. Introduction
Section 35.4.3. Rheumatoid arthritis
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
11/09/2017
Fouquet 2017 [966]Section 18.4.1. HLC assays are quantitative and non-subjective
Section 18.4.4. HLC assays improve detection of relapse
07/07/2017
EHA 2017 abstracts Section 14.4. The prognostic value of changes in monoclonal protein concentration
Section 15.1. Diagnosis of light chain multiple myeloma
Section 15.2. Monitoring light chain multiple myeloma
Section 17.6. Immunoglobulin HLC immunoassays (Hevylite) at diagnosis
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
26/05/2017
ASCO 2017 abstracts Section 14.4. The prognostic value of changes in monoclonal protein concentration
Section 28.7. Prognostic value of sFLC response
22/05/2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [954]Section 25.4. European Society of Medical Oncology: clinical practice guidelines for diagnosis, treatment and follow-up of multiple myeloma (2017)
03/05/2017
NCCN clinical practice guidelines in Oncology for Multiple Myeloma [592]Section 25.8. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2017
20/04/2017
Palladini 2017 [945]Section 8.5.7. Diagnostic performance in cast nephropathy
Section 8.5.8. Diagnostic performance in AL amyloidosis
20/04/2017
Andrade-Campos 2017 [950]Section 32.4.3. IgM HLC and WM prognosis
Section 32.5. Use of sFLC and HLC analysis to differentiate IgM MGUS, asymptomatic WM and WM
29/03/2017
IMW 2017 abstracts Section 8.2. Overview of commercial FLC assays
Section 12.4. Improving our understanding of disease pathogenesis and response to therapy
Section 18.3.5. Monitoring patients treated with monoclonal antibody-based therapies
Section 18.4.1. HLC assays are quantitative and non-subjective
Section 20.2. sFLCs at diagnosis
Section 20.5. HLC analysis during response assessment
24/02/2017
Tacchetti 2016 [938]Section 20.3.3. Prognostic implications of relapse with FLCs
24/02/2017
Sarto 2016 [936]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
24/02/2017
Murata 2016 [937]Section 18.3.5. Monitoring patients treated with monoclonal antibody-based therapies
21/12/2016
Voortman 2016 [934]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
Section 36.3. Prognostic significance of CSF FLCs
21/12/2016
Zeman 2016 [933]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
21/12/2016
Dobson 2013 [935]Section 36.3. Prognostic significance of CSF FLCs

Figures

References